BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
Year: 2023
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
electroCore Provides Select First Quarter 2023 Financial Guidance
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…
electroCore Provides Select First Quarter 2023 Financial Guidance
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United…
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United…
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board…
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board…
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs…
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs…
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment…
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment…
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
— CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for…
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
— CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for…
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
— IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2,…